+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Narcolepsy Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997403
  • Report
  • March 2020
  • Region: Global
  • 122 pages
  • Mordor Intelligence


  • Jazz Pharmaceuticals plc
  • Novartis AG
  • Shionogi Inc
  • MORE
The global narcolepsy therapeutics market is anticipated to witness a CAGR of nearly 10.1% during the forecast period. Increasing prevalence of narcoleptic disorders across the world, rising stress level, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. As per the Narcolepsy Network, around 1 in every 2,000 people in the United States are affected by this condition.

Increase in awareness about target disease among the general population and governments is expected to propel the narcolepsy market. Rising number of people suffering from a host of narcoleptic disorders, including hallucinations, sleep paralysis, disrupted nocturnal sleep, and obesity has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. For instance, awareness campaigns conducted by various networks, such as the National Center on Sleep Disorders Research to address the needs of individuals with serious or mild narcoleptic conditions.

Approval and commercialization of new drugs by market players is also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2019, Jazz Pharmaceuticals received the U.S. FDA approval of Sunosi (solriamfetol) for the treatment of narcoleptic patients. However, delayed diagnosis or misdiagnosis may hamper the demand for narcolepsy therapeutics market.

Key Market Trends

Narcolepsy With Cataplexy Dominates the Market
  • Narcolepsy with cataplexy is expected to dominate the global narcolepsy theraputics market through the forecast period. This can be attributed to rising prevalnce of narcolepsy with cataplexy which causes severe, irresistible daytime sleepiness and sudden loss of muscle tone. As per the study of the National Sleep Foundation, almost 60-70% of narcoleptic patients suffer from narcolepsy with cataplexy.
  • Increasing awareness about the disease and the available treatment options leading to early diagnosis as well as increasing healthcare expenditure are the factors anticipated to drive this segment’s growth over the forecast period.
North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth

Currently, North America dominates the market studied and is expected to continue its strong hold for a few more years. Growing demand for sleep disorder treatment in the U.S. and Canada coupled with increasing prevalence of narcoleptic disorders, increase in awareness, and high healthcare spending are anticipated to drive the market. In addition, favorable reimbursement policies for therapeutic products, strong clinical pipeline, and rising stress level are other factors anticipated to promote revenue growth.

Asia Pacific is anticipated to witness a lucrative growth over the forecast period. Shift-work sleep disorder and increased stress level are expected to expand the patient base in Asia Pacific. These factors may contribute to the growing demand for drugs in these economies. Constantly improving healthcare reimbursement policies are expected to boost the demand over the forecast period. In addition, increasing living standards have spurred the regional demand. All these factors are anticipated to bode well for regional market growth in the forthcoming years.

Competitive Landscape

The major players include companies such as Arena Pharmaceuticals, Inc., BIOPROJET, Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals USA, Inc.

Collaborations and acquisitions over the next few years to share technology and costs for innovation in the field are expected to be observed. For instance, Takeda completed the acquisition of Shire in January 2019, overtaking PROVIGIL product, which is the popular selling narcolepsy drug.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Jazz Pharmaceuticals plc
  • Novartis AG
  • Shionogi Inc
  • MORE
1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of Narcolepsy
4.2.2 Narcolepsy Awareness Programs and Services
4.2.3 Presence of Reimbursement Policies Regarding Narcolepsy
4.3 Market Restraints
4.3.1 Adverse Effects and Risks Related to Narcolepsy Drugs
4.3.2 Delayed Diagnosis or Misdiagnosis
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Narcolepsy with Cataplexy
5.1.2 Narcolepsy without Cataplexy
5.1.3 Secondary Narcolepsy
5.2 By Product
5.2.1 Central Nervous System Stimulants
5.2.2 Sodium Oxybate
5.2.3 Selective Serotonin Reuptake Inhibitor
5.2.4 Tricyclic Antidepressants
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Arena Pharmaceuticals, Inc.
6.1.3 Jazz Pharmaceuticals plc
6.1.4 Ligand Pharmaceuticals Incorporated
6.1.5 Novartis AG
6.1.6 Shionogi Inc
6.1.7 Takeda Pharmaceutical Company
6.1.8 Teva Pharmaceuticals Industries Ltd.

Note: Product cover images may vary from those shown
  • Arena Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Ligand Pharmaceuticals Incorporated
  • Novartis AG
  • Shionogi Inc
  • Takeda Pharmaceutical Company
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown